Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

ProPAC-COVID, 2021
 
NCT04322396
RCTazithromycin plus hydroxychloroquineplaceboCOVID 19 hospitalizedlow
61/56 inconclusive

    COVID-19 mild to moderate meta-analysis

    Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020
     
    NCT04322123
    RCTazithromycin plus hydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
    217/227 safety concern
    • inconclusive 1 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 1.2-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 2.5-fold increase in elevated liver enzymes with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 8.8-fold increase in long QT with a moderate degree of certainty due to some concern in risk of bias
    7 studies excluded by filtering options (1 RCT / 6 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).